Clinical Trials
49 trialsStudy of Factors Regulating Mast Cell Proliferation
National Institutes of Health Clinical Center (CC)
(Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosis
Cogent Biosciences, Inc.
Screening Study for KIT D816V Mutated Mast Cell Disease in Select Populations
Blueprint Medicines Corporation
APEX
Cogent Biosciences, Inc.
DATAMAST
Imagine Institute
An Observational Study in Participants With Indolent Systemic Mastocytosis (ISM)
Blueprint Medicines Corporation
A Non-Interventional Study in Participants With Indolent Systemic Mastocytosis (ISM) in Germany
Blueprint Medicines Corporation
A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies
Thomas Jefferson University
EGR2
Assistance Publique - Hôpitaux de Paris
Institutional Registry of Rare Diseases
Hospital Italiano de Buenos Aires
IgE-PhD
KU Leuven
Dasatinib as Therapy for Myeloproliferative Disorders (MPDs)
M.D. Anderson Cancer Center
KID-Tryp
Assistance Publique - Hôpitaux de Paris
SARS
National Institute of Allergy and Infectious Diseases (NIAID)
Cromoglicate in Mastocytosis
LEO Pharma
Myeloproliferative Neoplasms (MPNs) Patient Registry
University Health Network, Toronto
MastoR
University of Zurich
Relationship Between Circulating Sclerostin and Bone Lesions in Patients With Mastocytosis
Medical University of Lublin
MastCellHet
University Hospital, Toulouse
Angioedema Biomarker Research Study
Foundation For Rare Disease Research
DALY-MAST
University Hospital, Toulouse
Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis Unresponsive to Optimal Symptomatic Treatment
AB Science
Study of Mast Cell Precursors
National Institutes of Health Clinical Center (CC)
Therapy of HES, PV, Atypical Chronic Myelocytic Leukemia (CML) or Chronic Myelomonocytic Leukemia (CMML), and Mastocytosis With Imatinib Mesylate
M.D. Anderson Cancer Center
HCQMa
University Hospital, Toulouse
Mast Cell Connect: A Registry for Patients With Mastocytosis
Blueprint Medicines Corporation
MCD&BuDi
University Hospital, Toulouse
Mast Cell Activation Test in Allergic Disease
Hong Kong Sanatorium & Hospital
Cause and Natural Course of Pediatric-Onset Mastocytosis
National Institutes of Health Clinical Center (CC)
AB06006
AB Science
Evaluation and Long-Term Follow-Up of Patients With Allergic and Inflammatory Disorders
National Institutes of Health Clinical Center (CC)
The Significance of Blood-tryptase and c-Kit Mutation in Insect Venom Immunotherapy
Meir Medical Center
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AK002
Allakos Inc.
Efficacy of AB1010 in Patients With Systemic Indolent Mastocytosis
AB Science
Masitinib in Patients With Mastocytosis With Handicap and Bearing the D816V Mutation
AB Science
BioUV2017
Medical University of Graz
Stem Cell Transplantation to Treat Systemic Mastocytosis
National Institutes of Health Clinical Center (CC)
Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases
Novartis
Molecular Mechanisms and Diagnosis of Mastocytosis
University of Michigan
SMART
Charite University, Berlin, Germany
Treatment of Indolent Systemic Mastocytosis With PA101
Patara Pharma
Imatinib in KIT-negative Systemic Mastocytosis
Hospital Virgen de la Salud
Cladribine Plus Pegylated Interpheron Alfa-2a in Systemic Mastocytosis
Hospital Virgen de la Salud
XOLMA
University of Zurich
Midostaurin in Indolent Systemic Mastocytosis
University Medical Center Groningen
UP
Medical College of Wisconsin
Characteristics of Mast Cells in Mastocytosis
National Institutes of Health Clinical Center (CC)
Blood Factors in Mastocytosis and Unexplained Anaphylaxis and Flushing
National Institutes of Health Clinical Center (CC)
Cytokine Production Patterns in Patients With Systemic Mastocytosis Compared With Atopic Dermatitis and Healthy Individuals
National Institutes of Health Clinical Center (CC)